Foamix Pharmaceuticals Ltd.
2 Holzman Street, Weizmann Science Park
Rehovot 7670402, Israel
March 10, 2017
BY EDGAR
Suzanne Hayes
Assistant Director
Securities and Exchange Commission
Office of Healthcare and Insurance
100 F Street, N.E.
Washington, DC 20549
| | Re: | Foamix Pharmaceuticals Ltd. Registration Statement on Form F-3 (File No. 333-216224)
|
Dear Ms. Hayes:
Pursuant to Rule 461 under the Securities Act of 1933 (the “Securities Act”), Foamix Pharmaceuticals Ltd. hereby requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission so that the Registration Statement, as amended, will become effective under the Securities Act at 5:00 p.m. ET on March 14, 2017 or as soon thereafter as practicable.
We request that we be notified of such effectiveness by a telephone call to Andrea L. Nicolas of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-3416 and that such effectiveness also be confirmed in writing.
| | Very truly yours,
FOAMIX PHARMACEUTICALS LTD. | |
| | | | |
| /s/ Ilan Hadar | |
| | By: | Ilan Hadar | |
| | Title: | Chief Financial Officer | |
| | | | |
| cc: | Phyllis G. Korff, Esq. Andrea L. Nicolas, Esq. Skadden, Arps, Slate, Meagher & Flom LLP Four Times Square New York, NY 10036 |
